FRISCO, Texas, March 22, 2022–(BUSINESS WIRE)–Magellan Healthcare, the behavioral and specialty healthcare segment of Magellan Health, Inc., published its updated clinical monograph: Appropriate Use of Psychotropic Drugs in Children and Adolescents.
As the country addresses the mental health crisis impacting children and adolescents, Magellan offers its clinical monograph highlighting evidence-based research on the use of psychotherapeutic agents in children and principles for optimal children’s psychopharmacotherapy practice–that underpins its model of care for serving children, youth and their families. The monograph serves as a resource for providers, clients, parents and other stakeholders to be informed and support decision making on behavioral health treatment options for children and adolescents.
In the face of increasing rates of psychotropic drug prescribing in the treatment of young people, Magellan’s monograph provides an in-depth analysis and outlines the need for:
Improved collaborative care for children’s behavioral health
Increased use of non-pharmacologic interventions for youth in general and foster care youth in particular
Consistent approaches to assessment, diagnosis, treatment, oversight and monitoring
Active family participation and understanding of the child’s illness and challenges they face
"Magellan is proud to contribute this valuable compendium of information and research as we demonstrate a continued commitment to children’s behavioral health and addressing the national children’s mental health crisis," said Magellan Healthcare Medical Director Louis Parrott, M.D., Ph.D., and the monograph’s lead author. "Now, more than ever, the behavioral health treatment options for our children and youth must be evidence-based. Our monograph supports this notion through packaging the most up-to-date evidence-based research to serve as a reference for providers and families in making informed and safe decisions on the use of psychotropic drugs in kids."
The January 2022 revision covers the following topics, and provides an updated listing of psychotropic drugs, and associated information, commonly prescribed for children:
Nature and scope of the problem
Children in foster care
Controversies in clinical management
Principles for optimal psychopharmacotherapy practice
Research evidence for treatment efficacy of psychotherapeutic agents, including mood disorders, obsessive-compulsive disorder, anxiety disorders, post-traumatic stress disorder, disruptive behavioral disorders/aggression, attention-deficit/hyperactivity disorder, developmental disabilities and eating disorders
Drug treatment effects on nervous system development
This resource is available along with Magellan’s award-winning monograph, Understanding and Meeting the Needs of Children and Adolescents at High Risk: Foundations of a Model, which highlights evidence-based prevention and treatment approaches for problematic behaviors and various types of behavioral health challenges in children and adolescents. Both provide valuable insights and information to support the critical behavioral health needs of our nation’s children.
Learn more and access the monographs and overview documents at MagellanHealthcare.com/Monographs.
About Magellan Healthcare: Magellan Healthcare, Inc., the healthcare business unit of Magellan Health, Inc., offers solutions for complex conditions in the areas of behavioral health and medical specialty treatment. Magellan Healthcare serves commercial health plans, employers, state and local governments, and the Federal government, including the Department of Defense. For more information, visit MagellanHealthcare.com.
About Magellan Health: Magellan Health, Inc. is a leader in managing the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits and other specialty areas of healthcare. Magellan supports innovative ways of accessing better health through technology, while remaining focused on the critical personal relationships that are necessary to achieve a healthy, vibrant life. Magellan's customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators. For more information, visit MagellanHealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322005264/en/
Media Contact: Lilly Ackley, firstname.lastname@example.org, (860) 507-1923
Though the number of COVID cases has dramatically decreased since the beginning of the year, there’s still a significant number of people around the world who remain unvaccinated.
Biotech giant Biogen (NASDAQ: BIIB) has generated many headlines in the past couple of years, largely due to its Alzheimer's disease (AD) therapy, Aduhelm, and that drug's controversial path to approval in the U.S. However, this landmark regulatory win hasn't been enough to save Biogen's performance. Let's look at two red flags that Biogen is currently facing and discuss whether it is worth it to purchase the company's shares right now. Drugmakers typically benefit from patents that allow them to sell their products on the market without worrying about cheaper generic competition, at least for a set period.
The nation’s three major credit bureaus say they are overhauling how they include medical debt in a consumer’s credit history. The agencies said the removal will result in nearly 70% of the medical debt on Americans’ credit reports. This is a case where less is more for the financial lives of many consumers, certainly during the pandemic, advocates say — but they note the people who will remain stuck with medical debt on their reports are likely going to be those who were already the most financially vulnerable.
Eleven lots of drugs recalled for having too much nitrosamine.
Nina Agdal, 29, just revealed her strong abs and booty in a brand new nude photo on Instagram. Fasting, yoga, boxing, and spin classes help her stay fit.
Pfizer Inc said on Monday it was recalling some lots of blood pressure drug Accuretic and two authorized cheaper versions of the drug due to the presence of elevated levels of a nitrosamine, a potential cancer-causing impurity. Pfizer said https://www.pfizer.com/news/press-release/press-release-detail/pfizer-voluntary-nationwide-recall-lots-accuretictm it has not received any reports of adverse events related to the drug till date. Nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables.
The company suffered a setback with its proprietary abuse-deterrent formulation of dextroamphetamine to treat ADHD.
Canopy Growth Corporation's ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC) scientific research team has announced positive results from a six-month, randomized clinical trial studying the effects of cannabidiol (CBD) on menstrual-related symptoms. This study was conducted in collaboration with Dr. Jessica G. Irons and Morgan L. Ferretti at James Madison University in Harrisonburg, Virginia. Nearly 75% of reproductive-aged menstruating individuals report experiencing unpleasant mens
YouTuber Cam Jones, one of the Goal Guys, breaks down the effects, both good and bad, of cutting all added sugar from his diet for 30 days.
COVID numbers are still steadily falling in the U.S. following Omicron's worrisome winter surge. According to the Centers for Disease Control and Prevention (CDC), infections were down by more than 16 percent in the last week, while hospitalizations had fallen by over 27 percent. But even as we enjoy some reprieve from the coronavirus, other countries around the world are once again being hit with an uptick in cases and hospitalizations thanks to a new COVID variant.RELATED: Dr. Fauci Just Issue
Aeterna Zentaris Inc (NASDAQ: AEZS) provided an update for its ongoing pivotal Phase 3 study AEZS-130-P02 (the DETECT-trial) of macimorelin to diagnose childhood-onset growth hormone deficiency (CGHD). The DETECT trial investigates the efficacy and safety of a single oral dose of 1.0 mg/kg macimorelin acetate as a growth hormone stimulation test (GHST) in pediatric patients with suspected growth hormone deficiency (GHD). The study will include approximately 100 subjects in Europe and North Ameri
Bella Thorne just showed off her sculpted abs and legs in a new bikini photo on Instagram. To stay fit, Bella does weight lifting, boxing, yoga, and Pilates.
The attorney for a former Tennessee nurse on trial in the death of a patient accidentally injected with a paralyzing drug told jurors Tuesday the woman is being blamed for systemic problems at Vanderbilt University Medical Center. RaDonda Vaught, 37, is facing a charge of reckless homicide for administering the drug vecuronium to 75-year-old Charlene Murphey instead of the sedative Versed on Dec. 26, 2017. Murphey had been admitted to the hospital two days earlier after developing a headache and losing vision in one eye.
Experts say it's possible to be going through perimenopause — the transition period before menopause — and not realize it. But there are some symptoms to look out for.
Julianne Hough, 33, just revealed her toned butt and legs in a brand new Instagram video. Spin classes, strength training, and green juices are her must-haves.
New coronavirus cases leaped in Michigan in the week ending Sunday, rising 11.6% as 6,651 cases were reported. The previous week had 5,961 new cases of the virus that causes COVID-19.
STORY: Drugmaker AstraZeneca said on Monday (March 21) that its Covid drug was effective against against new versions of the Omicron variant, including the highly contagious BA.2. That's according to an independent study. AstraZeneca said back in December that another lab study found that Evusheld retained neutralising activity against the BA.1 version of Omicron, which was the first to spread internationally late last year.The company said in a statement that data from the latest study showed the therapy reduced the viral load of all so-called "sublineages" of Omicron in mice lungs.The study has yet to be peer reviewed.Britain's drug regulator said last week that Evusheld was found to cut the risk of developing symptomatic COVID-19 by 77% in trials, It made the announcement after approving the therapy for preventing infections in adults with poor immune response.It's also been shown to save lives and prevent disease progression when given within a week of first symptoms.The therapy is currently under a European review and has already been authorised in the United States.
The BA.2 variant has already caused lockdowns in multiple countries and is now found in 12 percent of new cases in Georgia.
A man who asked his daughter-in-law an “invasive” question about pregnancy is wondering whether he violated her privacy (spoiler alert: yes, he did). Here’s how it happened, according to a Reddit user who posted on the website’s “Am I The A**hole” forum. The OP (original poster) and his wife began noticing that their daughter-in-law always […]
Back in 2007, 45-year-old Eugene Charlesworth modelled for Men’s Health. Now 60 and just as fit, we caught up with him to find out the secrets to ageing and training gracefully